Arbutus Biopharma Shares Fall 19% On European Patent Revocation

The European Patent Office's Board of Appeal verbally revoked Arbutus Biopharma's key LNP patent (EP2279254) after opposition proceedings by Moderna and Merck affiliates, undermining a central asset underpinning Arbutus's licensing and litigation strategy against Moderna and potentially reducing future royalty leverage. Arbutus says the revocation rests on an 'added matter' standard not used in the U.S., Japan or Canada and intends to petition for review when the written decision is issued; the company reported ~$93.7 million in cash at end-Q3 2025. The stock plunged 19.05% to $3.79 (52-week range $2.71–$5.10) on the news, signaling material investor concern despite management asserting a broader LNP patent portfolio remains.

Analysis

Market structure: The EPO revocation materially weakens Arbutus’s (ABUS) licensing leverage versus Moderna (MRNA) and large pharma; ABUS shares fell 19% to $3.79, signaling the market is pricing material royalty/settlement downside. Moderna and other LNP/IP-rich majors are the near-term beneficiaries as bargaining power and royalty exposure compress, increasing their effective pricing power in RNA delivery licensing. Expect smaller biotech LNP licensors to trade with higher implied legal risk premia; IP-dependent M&A/partnership valuations will be re‑rated downward by ~20–40% relative to pre-ruling expectations.

Risk assessment: Tail risks include a cascade of additional oppositions or adverse rulings in other jurisdictions and potential covenant/royalty clawbacks that could force ABUS to seek dilutive financing; if cash drops below ~$50M within 12 months management may need equity raises that dilute >25%. Short-term (days–weeks) volatility will be driven by the written EPO reasons (expected within ~30–60 days) and any immediate petition for review; medium-term (3–12 months) outcomes hinge on US/Japan/Canada litigation which the company says are unaffected. Hidden dependencies include contingent license clauses and counterparties’ willingness to settle rather than litigate, which could flip outcomes quickly.

Trade implications: Tactical short ABUS exposure via 3–6 month put spreads sized 1–2% of portfolio is recommended, with an add-on if ABUS breaches $3.20 (add to 3% port.). Pair trade: long MRNA small cap-weighted (0.5–1%) to capture reduced legal overhang and buy 6–9 month calls if implied vol cheapens; execute short ABUS/long MRNA to neutralize biotech beta. Reduce small-cap biotech exposure by 2–4% and rotate into large-cap, balance-sheet-strong vaccine/biotech names over 1–3 months.

Contrarian angles: The market may be over-pricing permanent loss—EPO revocation cites "added matter" and may not impact US/Japan/Canada cases, leaving upside if US courts or appeals preserve key claims; historical precedent shows EU board decisions can be reversed or lead to settlements that preserve value. If ABUS retains >$80M cash and wins US cases or settles for modest royalties, >2x recovery is plausible within 12–24 months; consider a distressed long only after the written decision if price < $2.50 and cash/runway metrics indicate <20% dilution risk.

Key Decisions for Investors

• Establish a tactical short on ABUS sized 1–2% of portfolio via 3–6 month put spreads (e.g., buy 6‑month $3.50/$2.50 put spread) to limit capital at risk; increase to 3% if ABUS breaches $3.20.
• Open a pair trade: long MRNA (0.5–1% portfolio) funded by the ABUS short to capture reduced counterparty leverage; alternatively buy 6–9 month MRNA calls if implied vol < historical 90‑day average by >10%.
• Reduce small-cap biotech exposure by 2–4% over the next 30 days and redeploy into large-cap vaccine/therapy names (e.g., MRNA) with >$5B market cap and >12 months of cash runway.
• Do not initiate new outright long ABUS positions until the EPO written decision is published (monitor 30–60 day window) and management files its petition for review; consider a speculative long only if ABUS < $2.50 AND cash > $70M (implying <20% dilution risk within 12 months).